• 제목/요약/키워드: Inflammatory Bowel Disease (IBD)

검색결과 148건 처리시간 0.028초

웃음치료가 염증성 장질환 환자의 불안 및 우울에 미치는 효과 (The Effects of Laughter Therapy on the Anxiety and Depression of Inflammatory Bowel Disease Patients)

  • 박소영;곽은아;허정은;신은경;김지현;이지윤;이지희
    • 임상간호연구
    • /
    • 제19권1호
    • /
    • pp.105-114
    • /
    • 2013
  • Purpose: The purpose of this study was to apply laughter therapy to clinical practice and investigate its effects on patients' anxiety and depression in order to increase the quality of nursing for patients with inflammatory bowel disease (IBD). Methods: The study was conducted based on the non-equivalent control group pretestposttest design. The participants include 20 patients with IBD in the control group and 17 in the experiment group. Data was collected from July 10th, 2011 to January 22nd, 2012. Laughter therapy was administered once a day for five consecutive days. Results: The anxiety score was significantly different between the two groups and indicates that laughter therapy is effective for reducing anxiety among patients with IBD. Futhermore, there were differences in the depression scores of the experiment group between the pre-test and post-test, but no significant differences were found between the two groups. Conclusion: The results show that laughter therapy was effective in reducing anxiety among patients with IBD but did not decrease depression directly. Considering that the experiment group had a bigger reduction rate in depression scores than the control group. However, it is expected that laughter therapy will serve as an emotional nursing intervention for patients with IBD.

Treatment with Extracellular Vesicles from Giardia lamblia Alleviates Dextran Sulfate Sodium-Induced Colitis in C57BL/6 Mice

  • Kim, Hyun Jung;Lee, Young-Ju;Back, Seon-Ok;Cho, Shin-Hyeong;Lee, Hee-Il;Lee, Myoung-Ro
    • Parasites, Hosts and Diseases
    • /
    • 제60권5호
    • /
    • pp.309-315
    • /
    • 2022
  • Inflammatory bowel disease (IBD) is a chronic and recurrent illness of the gastrointestinal tract. Treatment of IBD traditionally involves the use of aminosalicylic acid and steroids, while these drugs has been associated with untoward effects and refractoriness. The absence of effective treatment regimen against IBD has led to the exploration of new targets. Parasites are promising as an alternative therapy for IBD. Recent studies have highlighted the use of parasite-derived substances, such as excretory secretory products, extracellular vesicles (EVs), and exosomes, for the treatment of IBD. In this report, we examined whether EVs secreted by Giardia lamblia could prevent colitis in a mouse model. G. lamblia EVs (GlEVs) were prepared from in vitro cultures of Giardia trophozoites. Clinical signs, microscopic colon tissue inflammation, and cytokine expression levels were detected to assess the effect of GlEV treatment on dextran sulfate sodium (DSS)-induced experimental murine colitis. The administration of GlEVs prior to DSS challenge reduced the expression levels of pro-inflammatory cytokines, including tumor necrosis factor alpha, interleukin 1 beta, and interferon gamma. Our results indicate that GlEV can exert preventive effects and possess therapeutic properties against DSS-induced colitis.

A Pediatric Case of Inflammatory Bowel Disease with Renal Amyloidosis

  • Hyun, Hyesun;Park, Eujin;Kim, Ji Hyun;Cho, Myung Hyun;Kang, Hee Gyung;Moon, Jin Soo;Moon, Kyung Chul;Ha, Il-Soo;Cheong, Hae Il
    • Childhood Kidney Diseases
    • /
    • 제22권2호
    • /
    • pp.81-85
    • /
    • 2018
  • Amyloidosis is a rare disease that results from the deposition of extracellular protein in various body tissues, causing progressive organ dysfunction. Secondary renal amyloidosis is a rare but serious complication of chronic inflammatory bowel disease, particularly in patients with Crohn's disease or ulcerative colitis. We report a case of secondary renal amyloidosis in a pediatric patient who reported a 16-year history of "very early onset inflammatory bowel disease". Intensive treatment including repeated infliximab infusions improved clinical parameters of inflammatory bowel disease, although renal dysfunction showed progression. Amyloidosis should be considered in patients with IBD, particularly if they suffered disease progression.

Use of Dual-Energy X-ray Absorptiometry in Children with Inflammatory Bowel Disease: A Large Single Centre Study

  • Jois, Asha;Perera, Sajini;Simm, Peter;Alex, George
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제25권6호
    • /
    • pp.473-480
    • /
    • 2022
  • Purpose: Low bone mineral density (BMD) is a complication in children with inflammatory bowel disease (IBD). There are limited data evaluating dual-energy x-ray absorptiometry (DXA) as a screening tool for low BMD in children with IBD. We performed a single site retrospective analysis of DXA use. Methods: Children aged 5-18 years with IBD diagnosed between 2013 to 2017 at the Royal Children's Hospital, Australia, were included. Patient demographics, measures of disease activity, DXA scores, and factors related to BMD were collected. Results: Over a median follow up of 5.1 (4-6.4) years, 72/239 (30.1%) children underwent DXA, and 28/239 (11.7%) children had a second DXA. Our DXA practice differed to consensus guidelines regarding initial screening based on height and/or body mass index (BMI) z-score (8/17 [47.1%]), and repeat surveillance (13/42 [31.0%]). Children had a median lumbar spine (LS) z-score -0.80 (-1.65-0.075). Children with LS z-score≤-2.0 (n=14) had lower weight (6.57 [1.78-23.7] vs. 51.1 [26.5-68.7], p=0.0002) and height centiles (3.62 [1.17-17.1] vs. 42 [16.9-67.1], p=0.0001), and higher faecal calprotectin (FCP) (3041 [1182-4192] vs. 585 [139-2419], p=0.009) compared to children with LS z-score>-2.0. No fractures were reported. Of 28 children who underwent a second DXA 1.6 (1.1-2.2) years following initial DXA, no significant change in z-scores occurred. Conclusion: Children with IBD had low BMD. In addition to height centile and weight centile, FCP was associated with lower BMD, and should be considered in DXA screening guidelines. Greater clinician awareness of DXA consensus guidelines is required. Future prospective studies are required.

Inflammatory Bowel disease에 있어서 식사와 생활환경과의 관련성

  • 임병우;조여원
    • 식품기술
    • /
    • 제15권1호
    • /
    • pp.48-51
    • /
    • 2002
  • Crohn ' s disease (CD)와 ulcerative colitis (UC)의 원인은 아직 확실하지 않다. 확립된 연구보고는 없으나 여러 가지 세균이나 바이러스가 원인일수도 있고, 장내세균이 증강인자일수도 있다. 또한, 서양식 식사도 장 점막의 상태와 점막투과성에 영향을 미치기 때문에 역시 증강인자라고 할 수 있다. 각가지의 생활습관도 inflammatory bowel disease (IBD) 발병에 영향을 미치는 요인으로 알려져 있지만, 이들에 대한 다 기능성인자를 규명하는 것은 아직 많은 기초적 연구가 필요하다.

  • PDF

Renal involvement in children and adolescents with inflammatory bowel disease

  • Jang, Hea Min;Baek, Hee Sun;Kim, Jung-Eun;Kim, Ju Young;Lee, Yeon Hee;Cho, Hee Yeon;Choe, Yon Ho;Kang, Ben;Choe, Byung-Ho;Choi, Bong Seok;Cho, Min Hyun
    • Clinical and Experimental Pediatrics
    • /
    • 제61권10호
    • /
    • pp.327-331
    • /
    • 2018
  • Purpose: The incidence of inflammatory bowel disease (IBD) is rapidly increasing, and several reports have described the renal complications of IBD. We sought to evaluate the clinical manifestations of renal complications in children with IBD in order to enable early detection and prompt treatment of the complications. Methods: We retrospectively reviewed the medical records of 456 children and adolescents aged <20 years who had been diagnosed with IBD since 2000. We analyzed patient age, sex, medication use, IBD disease activity, and clinical manifestations of renal symptoms. Results: Our study comprising 456 children with IBD included 299 boys (65.6%) and 157 girls (34.4%). The study included 346 children with Crohn disease and 110 children with ulcerative colitis. The incidence of kidney-related symptoms was 14.7%, which was significantly higher than that in normal children. We observed 26 children (38.8%) with isolated hematuria, 30 children (44.8%) with isolated proteinuria, and 11 children (16.4%) with hematuria and concomitant proteinuria. A renal biopsy was performed in 7 children. Histopathological examination revealed immunoglobulin A nephropathy in 5 children (71.4%). All children presented with mild disease and well-controlled disease activity of IBD. Conclusion: Children with IBD are more likely to show kidney-related symptoms than healthy children and adolescents are. Therefore, regular screening of urine and evaluation of renal function in such children are necessary for early detection of renal complications.

Anti-Inflammatory Effects of Fermented Products with Avena sativa on RAW264.7 and HT-29 Cells via Inhibition of Inflammatory Mediators

  • Shin, Jihun;Lee, Mina
    • Natural Product Sciences
    • /
    • 제26권3호
    • /
    • pp.244-251
    • /
    • 2020
  • This study investigated therapeutic candidates with anti-inflammatory potential among traditional dietary ingredients targeting inflammatory bowel disease (IBD). Both Avena sativa and traditional fermented products, such as Korean soy paste, are popular health foods. We investigated the anti-inflammatory effects of soy paste combined with A. sativa (KDA), compared with soy paste without A. sativa (KD) by evaluating the expression of pro-inflammatory cytokines in lipopolysaccharide-stimulated RAW264.7 mouse macrophages and HT-29 human colon epithelial cells. KDA significantly inhibited the production of nitric oxide (NO) and downregulated the pro-inflammatory cytokines, such as interleukin (IL)-1β, IL-6, and tumor necrosis factor-α in lipopolysaccharide (LPS)-induced RAW264.7 cells. In another in vitro experiment involving LPS-stimulated HT-29 cells, KDA suppressed the levels of IL-8, which is the chemokine elevated in IBD. In addition, KDA exhibited anti-oxidative properties, such as 2,2-diphenyl-1-picryl-hydrazyl-hydrate (DPPH) and 2,2'-azino-bis(3-ethylbenz-thiazoline-6-sulfonic acid) (ABTS) radical scavenging activity. Our findings revealed that A. sativa combined with soy paste exhibits a synergistic anti-inflammatory and anti-oxidant effect following fermentation. These results suggest that KDA may be used as a potential anti-inflammatory therapy against IBD.

Parent Perspectives of Diagnostic and Monitoring Tests Undertaken by Their Child with Inflammatory Bowel Disease

  • Ho, Shaun Siong Chung;Keenan, Jacqueline Ilene;Day, Andrew Stewart
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제24권1호
    • /
    • pp.19-29
    • /
    • 2021
  • Purpose: To assess parent perspectives of the current and potential future tests for their child with inflammatory bowel disease (IBD). Methods: New Zealand parents of a child with IBD were invited to complete an anonymous online survey. Experiences relating to their child's blood or faecal tests, medical imaging (abdominal ultrasound [US], abdominal computerised tomography [CT] and magnetic resonance enterography) and colonoscopy were collected. Perceived attitudes to potential future testing of urine, saliva, and breath, were sought. Results: Twenty-eight parents, 93% female completed the survey, and 86% were aged between 35 and 54 years. Baseline information was provided by parents for 27 of 28 children, 70.3% had Crohn's disease with a mean disease duration of 2.67 years. Blood tests were the most requested and completed tests, while CT was the least ordered and most refused test. Colonoscopy was rated as the least comfortable and generated the most worry. Explanation of test significantly improved parent's levels of understanding when their child had blood, faecal, imaging (US) or colonoscopy tests. Providing an explanation, test invasiveness and the impact of the blood results may have on their child's treatment significantly improved parents' comfort levels. However, explanation of colonoscopy generated a significant parental concerns. Saliva, urine and blood tests were chosen as the most preferred disease monitoring tests. Conclusion: Parents preferred any tests less invasive than colonoscopy for monitoring their child's IBD. Although providing explanation of their child's tests enhanced parents' understanding, it can also affect parents' levels of concern and comfort.

시호추출물 (SHI-1909)의 염증성 대장염 실험동물 모델에 대한 치료효과 (Studies on Protective Effect of Bupleurum falcatum Extract (SHI-1909) against Experimental Inflammtory Bowel Disease Model)

  • 조성완;김영권
    • 한국산학기술학회논문지
    • /
    • 제10권3호
    • /
    • pp.613-619
    • /
    • 2009
  • SHI-1909를 초산과 TNBS에 의해 rat에 유발된 염증성 대장염 모델에서 5일 동안 경구 투여 하여 대조약인 프레드니솔론과 그 치료 효능을 비교 조사하였다. 7% 초산과 5% TNBS 용액을 polyethylene 튜브로 rat의 항문에 점적하여 염증성 대장염을 유발하였으며 점적 후 초산과 TNBS 대조군은 말단의 대장부위에서 궤양과 염증 증상 같은 병적인 소견을 보여 염증성 대장염이 잘 유발되었음을 확인할 수 있었다. 약물의 투약기간 중 염증 치유 변수인 실험동물의 중량과 식이 섭취량 변화를 관찰하였으며 실험이 종료된 후에는 실험동물을 희생시킨 후 대장의 길이와 궤양, 병적인 소견을 조사하였다. SHI-1909의 투여는 중량변화와 식이 섭취량 등에서 대조약과 필적할 만한 결과를 나타내었으며 특히 대장의 손상 정도 평가에서 대조약물인 프레드니솔론보다도 더 우수한 효과를 나타내었다. 이러한 결과로부터 SHI-1909는 IBD의 치료에 가능성이 있는 치료 약물이 될 수 있을 것으로 사료된다.

Reversal of Immunogenicity in Pediatric Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Medications

  • Kang, Elise;Khalili, Ali;Splawski, Judy;Sferra, Thomas J.;Moses, Jonathan
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제21권4호
    • /
    • pp.329-335
    • /
    • 2018
  • Loss of response to anti-tumor necrosis factor (anti-TNF) agents in the treatment of inflammatory bowel disease (IBD) is a major consideration to maintain sustained response. Reversal of immunogenicity can re-establish response and increase the durability of these agents. Strategies to reverse immunogenicity include dose-intensification and/or the addition of an immunomodulator. However, there is a relative paucity of data on the efficacy of such interventions in pediatric IBD patients. Available reports have not strictly utilized homogenous mobility shift assay, which reports on anti-drug antibodies even in the presence of detectable drug, whereas prior studies have been confounded by the use of drug sensitive assays. We report four pediatric inflammatory bowel disease patients with successful reversal of immunogenicity on an anti-TNF agent using dose intensification and/or addition of an immunomodulator.